Illustrations-2.jpg


We know a good thing when we see it.

 

And we know what it takes to make it into something great.

So, we only look for companies with real promise, not mere potential.

Outstanding teams, sound business model, strong forecasts, global potential, and the power to disrupt. Then we inject all our know-how and might, plus a good dose of entrepreneurial spirit, to take them from today’s stand-out performers, to tomorrow’s global players.

We are exceedingly proud of our portfolio companies and the people who drive them. Read more about them here.

Flat-Colour3.png

OneVentures Innovation Fund I


  Single application head lice treatment   Rights for human health applications in certain territories acquired by Dr.Reddy's for US$197M (September 2015)

Single application head lice treatment

Rights for human health applications in certain territories acquired by Dr.Reddy's for US$197M (September 2015)

  Media telecommunications company (MVNO)   Led merger between My Mobile Data (t/as OVO Mobile) and Incoming Media (December 2017)

Media telecommunications company (MVNO)

Led merger between My Mobile Data (t/as OVO Mobile) and Incoming Media (December 2017)

  Microprojection array (Nanopatch) for intradermal vaccine delivery   Led syndicate for $15M Series A financing (August 2011)  Led $33M Series B financing (February 2015)   Visit website

Microprojection array (Nanopatch) for intradermal vaccine delivery

Led syndicate for $15M Series A financing (August 2011)

Led $33M Series B financing (February 2015)

Visit website

  Adaptive e-learning platform   Led Series A (October 2011)  $10M Series B (December 2013)  Led $5M C-Note financing (July 2016)  US$7.5M Series C (January 2018)   Visit website

Adaptive e-learning platform

Led Series A (October 2011)

$10M Series B (December 2013)

Led $5M C-Note financing (July 2016)

US$7.5M Series C (January 2018)

Visit website

  Oncology information systems   Led acquisition by The Citadel Group (ASX:CGL) for ~$10.8M (September 2017)

Oncology information systems

Led acquisition by The Citadel Group (ASX:CGL) for ~$10.8M (September 2017)

  Building energy management software   Investment realised, IRR 70% (December 2012)

Building energy management software

Investment realised, IRR 70% (December 2012)

  Video engagement platform   Led $4.9M Series A with participation by Intel and Warner Music (October 2014)  Led  Series A2 investment into Incoming Media (July 2017)  Acquired by My Mobile Data (December 2017)   Visit website

Video engagement platform

Led $4.9M Series A with participation by Intel and Warner Music (October 2014)

Led  Series A2 investment into Incoming Media (July 2017)

Acquired by My Mobile Data (December 2017)

Visit website

 

OneVentures Innovation & Growth Fund II


  Wearables for the vulnerable   Led $4M Series A (December 2015)

Wearables for the vulnerable

Led $4M Series A (December 2015)

  Cloud-based HR platform   Led $4.5M Series A (July 2016)  Co-led with Seek Ventures $8M Series B (March 2018)

Cloud-based HR platform

Led $4.5M Series A (July 2016)

Co-led with Seek Ventures $8M Series B (March 2018)

  Cancer DNA diagnostics   US$15M Series A (April 2016)

Cancer DNA diagnostics

US$15M Series A (April 2016)

  Photo-realistic holographic technology platform   Contributed to a US$26.7M Series B financing led by Time Warner Investments (November 2016)

Photo-realistic holographic technology platform

Contributed to a US$26.7M Series B financing led by Time Warner Investments (November 2016)

  Microprojection array (Nanopatch) for intradermal vaccine delivery   Led syndicate for $15M Series A financing (August 2011)  Led $33M Series B financing (February 2015)   Visit website

Microprojection array (Nanopatch) for intradermal vaccine delivery

Led syndicate for $15M Series A financing (August 2011)

Led $33M Series B financing (February 2015)

Visit website

  Food allergy therapeutics   Led $15M Series A (September 2016)

Food allergy therapeutics

Led $15M Series A (September 2016)

 

OneVentures Healthcare Fund III


  Food allergy therapeutics   Led $15M Series A (September 2016)

Food allergy therapeutics

Led $15M Series A (September 2016)

  Total Artificial Heart (TAH) to replace complete function of a patient’s failing heart   Participated in Series A financing to fund the development of the external controller for the TAH (February 2018)

Total Artificial Heart (TAH) to replace complete function of a patient’s failing heart

Participated in Series A financing to fund the development of the external controller for the TAH (February 2018)

 
 
Block-BG-5.png